メインナビゲーションにスキップ
検索にスキップ
メインコンテンツにスキップ
藤田医科大学 ホーム
English
日本語
ホーム
プロファイル
研究部門
研究成果
専門知識、名前、または所属機関で検索
Scopus著者プロファイル
林 正道
医学部・内科学（第４）
h-index
536
被引用数
10
h 指数
Pureの文献数とScopusの被引用数に基づいて算出されます
2004
2024
年別の研究成果
概要
フィンガープリント
ネットワーク
研究成果
(43)
類似のプロファイル
(6)
フィンガープリント
Masamichi Hayashiが活動している研究トピックを掘り下げます。このトピックラベルは、この研究者の研究成果に基づきます。これらがまとまってユニークなフィンガープリントを構成します。
並べ替え順
重み付け
アルファベット順
Keyphrases
Sleep-disordered Breathing
33%
Magnesium Supplementation
33%
Clinical Characterization
33%
Gender Differences
33%
Carbohydrate Antigen 19-9 (CA19-9)
33%
Cisplatin Nephrotoxicity
33%
Peripheral Lung Lesion
33%
Clinical Features
33%
Bronchus Sign
33%
Transbronchial Biopsy
33%
Endobronchial Ultrasound with a Guide Sheath
33%
Tyrosine Kinase Inhibitor Therapy
33%
Diagnosis-to-treatment Interval
33%
Sleep Apnea Syndrome
33%
Innominate Artery
33%
Diffuse Alveolar Hemorrhage
33%
Sleep Apnea
33%
Positive Airway Pressure Therapy
33%
Usual Interstitial Pneumonia Pattern
33%
Lymphocyte Profile
33%
Mediastinal Lymphadenopathy
33%
Self-efficacy
33%
Split Dose
33%
Vinorelbine
33%
Afatinib
33%
β-agonists
33%
Aspirin-induced Asthma
33%
Human Peripheral Blood Monocytes
33%
Portable Monitoring Device
33%
Activating EGFR mutation
33%
Treatment Cascade
33%
Sheet-like Structure
33%
Silicone Spigot
33%
Endobronchial Watanabe Spigot
33%
Curette
33%
Amrubicin
33%
Continuous Ambulatory Peritoneal Dialysis
33%
Interstitial Pneumonia
33%
Short Hydration
33%
Nonspecific Interstitial Pneumonia
33%
Bronchial Occlusion
33%
Epithelium-like Cells
33%
Metabolic Syndrome
29%
Endobronchial Ultrasonography with a Guide Sheath (EBUS-GS)
27%
Organoids
27%
Mepolizumab
20%
Bronchi
14%
CD11b Expression
14%
Obstructive Sleep Apnea
13%
Right Aortic Arch
13%
Pharmacology, Toxicology and Pharmaceutical Science
Sleep Disordered Breathing
100%
Non Small Cell Lung Cancer
66%
Disease
46%
Pemetrexed
33%
Interstitial Pneumonia
33%
Cisplatin
33%
Lung Hemorrhage
33%
Symptom
33%
Vinorelbine
33%
Afatinib
33%
Beta Adrenergic Receptor Stimulating Agent
33%
Monotherapy
33%
Syndrome
33%
Amrubicin
33%
Aspirin Exacerbated Respiratory Disease
33%
Clinical Feature
33%
Neutropenia
16%
Progression Free Survival
16%
Epidermal Growth Factor Receptor
16%
Stage Specific Embryo Antigen 1
16%
Podoplanin
16%
Comorbidity
15%
Lactate Dehydrogenase
13%
Recurrence Free Survival
11%
Acute Respiratory Failure
9%
Rash
8%
Thrombocytopenia
8%
Leukopenia
8%
Febrile Neutropenia
8%
Remdesivir
8%
Survival Rate
8%
Bovine Serum Albumin
8%
Adverse Event
8%
Median Survival Time
8%
Anorexia
8%
Fluoropyrimidine Derivative
8%
Chemotherapy
8%
Cohort Study
8%
Aminotransferase
8%
Hospital Mortality
8%
Anemia
8%
Infection
8%
Dexamethasone
8%
Disease Course
8%
Gastroenteritis
8%
Retrospective Study
6%
Somnolence
6%
Diabetes Mellitus
6%
Medicine and Dentistry
Endobronchial Ultrasonography
66%
Transbronchial Biopsy
66%
Peripheral Lung Lesion
36%
Pulmonary Hemorrhage
33%
Disease Exacerbation
33%
Brachiocephalic Artery
33%
COVID-19
33%
Clinical Feature
33%
Symptom
33%
Mediastinal Lymphadenopathy
33%
Bronchus Obstruction
33%
Curette
33%
Amrubicin
33%
Continuous Ambulatory Peritoneal Dialysis
33%
Gefitinib
33%
Infectious Complication
33%
Pharmacokinetics
33%
Idiopathic Interstitial Pneumonia
33%
CA19-9
33%
Infection
18%
Antiviral Therapy
16%
Disease
15%
Mepolizumab
14%
Hemoptysis
11%
Bronchoalveolar Lavage Fluid
11%
Acute Respiratory Failure
9%
Lactate Dehydrogenase
9%
Dupilumab
9%
Bronchoscopy
9%
Stenosis
9%
Antibiotics
9%
Serum Group
7%
Auscultation
6%
Aortic Arch Surgery
6%
Biopsy Technique
6%
Target Lesion
6%
Outpatient
5%
Clinical Management
5%
Coronavirinae
5%
Dyspnea
5%
Podoplanin
5%
Stage Specific Embryo Antigen 1
5%
Mouse Study
5%
Enzyme Therapy
5%
Diagnosis
5%
Remdesivir
5%
